Neuroinflammation in traumatic brain injury: A chronic response to an acute injury

Samantha J. Schimmel, Sandra Acosta, Diego Lozano

Abstract:
Every year, approximately 1.4 million US citizens visit emergency rooms for traumatic brain injuries. Formerly known as an acute injury, chronic neurodegenerative symptoms such as compromised motor skills, decreased cognitive abilities, and emotional and behavioral changes have caused the scientific community to consider chronic aspects of the disorder. The injury causing impact prompts multiple cell death processes, starting with neuronal necrosis, and progressing to various secondary cell death mechanisms. Secondary cell death mechanisms, including excitotoxicity, oxidative stress, mitochondrial dysfunction, blood–brain barrier disruption, and inflammation accompany chronic traumatic brain injury (TBI) and often contribute to long-term disabilities. One hallmark of both acute and chronic TBI is neuroinflammation. In acute stages, neuroinflammation is beneficial and stimulates an anti-inflammatory response to the damage. Conversely, in chronic TBI, excessive inflammation stimulates the aforementioned secondary cell death. Converting inflammatory cells from pro-inflammatory to anti-inflammatory may expand the therapeutic window for treating TBI, as inflammation plays a role in all stages of the injury. By expanding current research on the role of inflammation in TBI, treatment options and clinical outcomes for afflicted individuals may improve. This paper is a review article. Referred literature in this paper has been listed in the references section. The data sets supporting the conclusions of this article are available online by searching various databases, including PubMed. Some original points in this article come from the laboratory practice in our research center and the authors’ experiences.

Keywords:
Central nervous system disorders, neuroinflammation, neuroprotection, regenerative medicine, secondary cell death, stem cell therapy, traumatic brain injury

Introduction

A traumatic brain injury (TBI) is an injury caused by excessive force to the head that may cause external brain injury, brain dysfunction, or death. Every TBI is different, so duration of the damage may be either temporary or permanent.

Clinically, the Glasgow coma scale classifies the severity of TBI based on patient consciousness, motor skills, verbal abilities, and eye reflexes (the scale classifies scores of 3–8 as severe TBI, 9–13 as mild TBI, and 14–15 as moderate TBI, also known as a concussion). The severity of TBI cases may also be classified based on technological imaging machines and patients’ existing health conditions. While animal and human TBI pathologies are different, both display neuroinflammation postinjury.

Recent evidence suggests that TBI is not just an acute injury, as it shares chronic symptoms with diseases such as Parkinson’s and Alzheimer’s. The neuroinflammation associated with both chronic and acute TBI symptoms may be a central component of the injury, presenting...
In the United States, 30% of all injury-related deaths are from TBI. Annually, these injuries kill about 50,000 people, cause 1.4 million people to seek medical services, cause 235,000 hospitalizations, and leave 85,000 surviving individuals disabled. The widespread nature of TBI – it is estimated that 3.2–5.3 million people suffer from it has cost the US about $37.8 billion dollars ($4.5 billion for hospital and long-term treatments, $20.6 billion from disability or work complications, and $12.7 billion from untimely deaths). Socially speaking, TBI profoundly affects friends and families of afflicted individuals.

Because of the large amount of people vulnerable to TBI, more research is needed to come up with an effective treatment. The following study looks into neuroinflammation as a target for new treatments because of its occurrence in both acute and chronic stages of the injury.

Clinical Manifestations of Traumatic Brain Injury

Approximately 30%–80% of TBI victims suffer from symptoms following the initial injury. These symptoms often go away within the following hours or days, but occasionally individual cases will be faced with post-TBI symptoms for years or the rest of their lives. Factors such as increased severity of the injury, being female, older age, low socioeconomic status, and mental disorders all contribute to the intensity and duration of post-TBI symptoms.

The study focuses on mild TBI symptoms, due to the high prevalence of them, but TBI may also injure axons, bruise the brain, or even cause comas.

Physically, between 25% and 90% of patients with mild-TBI claim to suffer from headaches postinjury and several other patients experience nausea, dizziness, sleep disruptions, and visual and auditory complications. In addition, damage to the frontal or temporal lobe may cause TBI patients to experience seizures, which may prove to be an obstacle to treatment and diagnosis due to confusion with epilepsy.

Regarding cognitive symptoms, TBI patients may suffer from attention deficit, memory impairment, and overall executive function deficit. These symptoms are likely caused by injuries to the frontal lobe, subcortical systems, white matter tracts, and axons; these structures and systems are partially responsible for information processing, stamina, and mental speed.

Patients of mild TBI may also experience several behavioral (or personality) changes following the injury. These changes include mood shifts, irritability, aggression, lack of motivation, selfishness, depression, anxiety, and posttraumatic stress disorder. TBI patients are also at an increased risk of developing several neurodegenerative disorders (such as Parkinson’s disease and Alzheimer’s disease).

Finally, many patients present with epilepsy-like symptoms such as partial seizures that affect cognition, emotional processes, and inflammatory responses.

Secondary Cell Death and Neuroinflammation

Following TBI, several detrimental processes begin to affect the injured brain. Mechanical injury damage to neurons, axons, glia, and blood vessels initiates the primary injury. The degree of primary injury varies in each case of TBI and usually causes direct neural cell loss and necrotic cell death.

Primary injury next triggers various biochemical cascades that usually cause secondary cell death and prolonged neurodegeneration. These cascades occur seconds to minutes after the initial insult and can last anywhere from days to years following injury. The secondary cellular injuries primarily affect the site of injury and neighboring tissues but have the potential to spread throughout the brain. Secondary cell death processes consist of excitotoxicity, oxidative stress, mitochondrial impairment, damaging of the blood–brain barrier (BBB), and inflammation. The aforementioned processes often interact to further increase progressive neurodegeneration.

Excitotoxicity, a secondary cell death mechanism that may follow TBI, is characterized by the secretion of intracellular glutamate (a neurotransmitter) into extracellular spaces by injured nerve cells. The increased glutamate in the synaptic space overstimulates amino-3-hydroxy-5-methylisoxazole-4-propionic acid and N-methyl-d-aspartate subtype glutamate receptors, which in turn allows a flood of sodium and calcium ions into the cell. The increased calcium ions then activate protein phosphatases, phospholipases, and endonucleases to fragment DNA and other membranes and structures of the cell, eventually causing cell death by necrosis and apoptosis. In addition, the excess glutamate causes the creation of additional nitric oxide, free radicals, and prodeath transcription factors.

Oxidative stress is another secondary cell death mechanism attributed with abnormal levels of two free radicals, reactive oxygen species (ROS), and reactive radicals.
Neuroinflammation increases excess calcium ions cause cytokines, chemokines, and other inflammatory mechanisms and acts through immune cells, microglia, neural cell death by interfering with endogenous repair 17 years post-TBI. Finally, the major cause of secondary cell death following TBI is neuroinflammation. Neuroinflammation follows the initial impact and may persist up to 17 years post-TBI. Neuroinflammation increases neural cell death by interfering with endogenous repair mechanisms and acts through immune cells, microglia, cytokines, chemokines, and other inflammatory molecules. Initially, an inflammatory response is activated to repair damaged cells and protect the brain from invading pathogens. Following the activation of the inflammatory response, inflammatory cells, neutrophils, monocytes, and lymphocytes cross the BBB and release prostaglandins, pro-inflammatory cytokines, and other inflammation regulators. These regulators further recruit microglia and immune cells to the brain by increasing the expression of chemokines and cell adhesion molecules.

Microglia cells, which are systemic macrophages, initially benefit the brain post-TBI by separating healthy and injured tissues to limit the spread of damage. Microglial activation, however, becomes excessive and causes the release and upregulation of several pro-inflammatory cytokines, increased production of neurotoxic molecules and free radicals, and increased expression of major histocompatibility complex class II (MHCII+). The pro-inflammatory cytokines released tumor necrosis factor alpha (TNF)-α, interleukin (IL-1) β, IL-6, IL-12, and interferon δ increase the inflammatory response by weakening the BBB. The production of unnecessary neurotoxic molecules and free radicals initiates additional cell death mechanisms. Finally, the overexpression of MHCII+ contributes to neurodegeneration. Glial cells also contribute to an increased inflammatory response, as they express and produce chemokines that upregulate adhesion molecules. This upregulation eases leukocyte migration across the BBB, causing a further intensified immune response.

While microglia often promotes inflammation, they occasionally decrease inflammatory responses. Whether or not microglia promotes or decrease inflammation depends on their phenotype (which is determined by their microenvironment). Microglia with M1 phenotypes occur in the presence of lipopolysaccharide and interferon γ and stimulate the production of pro-inflammatory cytokines while discouraging production of anti-inflammatory cytokines (i.e., IL-10). In contrast, microglia develops the M2 phenotype when in contact with cytokines IL-4 or IL-13. M2 microglia decreases inflammation by reducing the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory molecules (IL-10, transforming growth factor 1 β, suppressor of cytokine signaling).

Astrocytes are also involved in injury sites post-TBI by working with neurotrophic factors to upregulate neurotrophic factors that aid in axonal repair, increase cell proliferation, aid in neuronal survival, and inhibit programmed cell death. In addition, astrocytes reduce glutamate excitotoxicity by regulating extracellular...
glutamate levels.\(^{[66]}\) While astrocytes produce beneficial effects post-TBI, excessive amounts of them often create a glial scar.\(^{[66,71]}\) A glial scar is a physical and chemical barrier that surrounds the injury site and is created when astrocytes produce an inhibitory cellular matrix.\(^{[66,71]}\) While glial scars do protect healthy portions of the brain from the neurotoxins of the injury site, it is damaging because it prevents efficient repair of damaged tissue.\(^{[66,71]}\)

**Neuroinflammation-based Therapies**

Since the primary injury is only treatable through preventative methods, most research focuses on secondary cell death. The delayed onset of neuroinflammation, compared to other secondary cell death processes, makes it a desirable treatment target.\(^{[72]}\) Since neuroinflammation does not occur immediately after the injury, there is a greater therapeutic window for the administration of treatments. Future treatments ought to focus on methods to enhance the protective effects of neuroinflammation while simultaneously eliminating detrimental side effects.

One potential drug that may be used to target TBI-related inflammation is minocycline, a safe tetracycline derivative with anti-inflammatory characteristics that can pass through intact BBBs.\(^{[73-77]}\) In animal studies, minocycline improved outcomes by decreasing inflammation and tissue damage.\(^{[77,78]}\) Minocycline controls inflammation through several mechanisms by acting with other inflammatory regulators to decrease the concentrations of pro-inflammatory cytokines and chemokines. This in turn reduces nitric oxide presence and prevents the over activation of microglia.\(^{[77,78]}\) Because microglia promotes the pro-inflammatory cytokines IL-1 \(\beta\), IL-6, and MMP-9, the reduction of microglial activity reduces inflammation.\(^{[78-80]}\) Even though minocycline has numerous anti-inflammatory properties, it has not proven to be very beneficial in TBI cases. Novel studies will need to examine whether the drug does not work in TBI or if the lack of therapeutic effect is due to factors such as dosage and method of administration.\(^{[79,81]}\)

Melatonin, a hormone produced from the pineal gland with neuroprotective properties, may also prove useful in treating TBI.\(^{[82,83]}\) Melatonin is a lipophilic enzyme, meaning that it can cross cell membranes, that decreases inflammation by inhibiting microglial activation and reducing pro-inflammatory cytokine concentrations (i.e., IL-1 \(\beta\) and TNF-\(\alpha\)).\(^{[89,90]}\) While some experimental trials have shown melatonin to reduce brain edema and cortical neuron degeneration, no cognitive benefits have been proven.\(^{[91]}\) A possible reason for the lack of observed cognitive improvement is incorrect treatment dosages,\(^{[81]}\) suggesting that melatonin may be able to repair inflammation-based secondary damage. Before melatonin can be translated into a clinical setting, studies will need to test the hormone’s long-term effects and safety in TBI-models.

Statins, cholesterol-lowering drugs, displayed anti-inflammatory, and neuroprotective properties in a mouse model of subarachnoid hemorrhage.\(^{[93]}\) Statins decrease microglia and astrocyte activation: microglia by inhibiting the signaling pathways of toll-like receptor 4, nuclear factor \(\kappa\)B (NF-\(\kappa\)B), and G-proteins and astrocytes through the inhibition of epidermal growth factor receptors.\(^{[98,94,95]}\) The reduced amount of microglia and astrocytes leads to a reduction of pro-inflammatory cytokines IL-1 \(\beta\) and TNF-\(\alpha\) and intracellular adhesion molecules.\(^{[38,93,95]}\) Statins have shown therapeutic effects in both animal and human TBI models. Preclinical studies have cited improved neuronal survival, growth, and differentiation\(^{[38]}\) while clinical studies using rosuvastin over 10 days reported slight improvements in disorientation and amnesia.\(^{[96]}\) While statins are relatively safe and predictable, more preclinical studies using the drug in TBI cases are needed to enhance clinical outcomes.

Another potential treatment option for TBI cases are stem cells, unspecialized cells with regenerative properties.\(^{[2,3,97]}\) Stem cells have lots of potential in TBI because of their high degree of proliferation, ability to provide trophic support to surviving host cells, regulation of inflammation, and their potential to differentiate into and replace specific cells (such as neurons).\(^{[2,3,98-102]}\) Stem cell therapy has been shown to improve cognitive and motor abilities, decrease inflammation and cell death, and promote regeneration.\(^{[3,103]}\) Stem cells are either derived from adults, embryos, and fetuses. Adult stem cells are less likely to form tumors, easier to control, and raise less moral questions; embryo and fetal stem cells show higher degrees of plasticity, release more trophic factors, and show higher degrees of proliferation.\(^{[2,3,71]}\)

Mesenchymal stem cells (MSCs) are particularly attractive for TBI treatments because they travel to the site of injury, regulate inflammation, proliferate, and activate other inflammatory cells.\(^{[104-106]}\) MSCs likely control inflammation through TNF-\(\alpha\)-stimulated gene/protein 6 (TSG-6). TSG-6, promoted by TNF-\(\alpha\) and IL-1, is an anti-inflammatory protein that inhibits the signaling pathway involved with toll-like receptors and NF-\(\kappa\)B, inactivates parts of hyaluronan, and modifies T-cell behavior.\(^{[104,107,108]}\) Because NF-\(\kappa\)B regulates genes involved in inflammation and the synthesis of pro-inflammatory cytokines, inhibiting NF-\(\kappa\)B impedes both the NF-\(\kappa\)B signaling pathway and the following pro-inflammatory effects.\(^{[107]}\) TSG-6’s inactivation of hyaluronan and modification of T-cell behavior also decreases inflammation, as hyaluronan is a pro-inflammatory molecule and T-cells go from
producing pro-inflammatory cytokines (interferon γ) to anti-inflammatory cytokines (IL-4).[107,108]

In addition, MSCs strengthen the BBB by reducing the synthesis of several chemokines implicated in increased BBB permeability (CXCL2, CCL2, and RATNES). These chemokines are often produced by neurons and microglia and may contribute to immune and inflammatory responses.[104] CXCL2 contributes to neutrophil infiltration, CCL2 is a chemoattractant that incites immune cell relocation, and RANTES aids in T-cell activation.[104,109] MSCs use transforming growth factor β to downregulate the chemokines, in particular, CCL2. Transforming growth factor β works by activating Smad3, which in turn reduces transcription of CCL2. The reduction of the chemokines serves as an anti-inflammatory method because of a subsequent reduction in the harmful effects of leukocytes, neutrophils, and microglia post-TBI.

A major issue with stem cell transplantsations is the stem cells’ low survival rate in the injured area.[110] If stem cells are used in conjunction with treatments that can improve the host environment, it is likely that a better therapeutic outcome will occur. One potential second treatment option is granulocyte-colony stimulating factor (G-CSF), a cytokine able to augment the benefits of endogenous stem cells.[3] G-CSF as an unaccompanied treatment slightly decreases inflammation, improves motor dysfunctions, decreases brain edema, and regulates glutamate levels. In addition, treatment consisting of human umbilical cord blood cells increases neurogenesis and slightly decreases hippocampal cell death. When the two treatments are combined, however, neurogenesis greatly improves, cell death significantly decreases, and therapeutic effects last longer.[3]

The US Food and Drug Administration has approved the usage of G-CSF as a drug due to its ability to enlist endogenous stem cells from the bone marrow into the blood stream for the purpose of promoting neuroprotection.[3] Furthermore, G-CSF is likely able to cross the BBB, bind to the G-CSF receptor on neurons and microglia, and promote therapeutic effects. These effects include a decreased concentration of inflammatory cytokines, increased angiogenesis in the brain, and decreased apoptosis.[3] Furthermore, bone marrow derived stem cells may indirectly affect the central nervous system by secreting trophic growth factors, chemokines, and cytokines that aid in neuroprotection and neuroregeneration.[3]

**Future Direction of Anti-inflammation as a Therapy for Traumatic Brain Injury**

Regulating neuroinflammation appears to be a strong potential treatment option for dealing with TBI, as it can be both detrimental and beneficial to the recovering brain. Immune cells, astrocytes, cytokines, and chemokines are all important to the brain’s recovery, but contribute to secondary death when present in excessive levels. Ideally, a treatment would be able to regulate the activation and deactivation of these cells to provide their needed benefits and avoid their hindrances. Additional studies are warranted to reveal cell death pathways relevant to inflammation, which should reveal insights on potential strategies in sequestering inflammation and its associated neurodegenerative processes. A complete understanding of TBI, inflammation, and disease progression will prove beneficial in improving clinical outcomes for TBI patients.

**Financial support and sponsorship**

SA is supported by NIH grant 1R21NS094087-01 and AHA Grant 16POST27790076.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008;7:728-41.
2. Tajiri N, Acosta SA, Shahaduzzaman M, Ishikawa H, Shinozuka K, Pabon M, et al. Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: Cell graft biodistribution and soluble factors in young and aged rats. J Neurosci 2014;34:313-26.
3. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Sanberg PR, Sanchez-Ramos J, et al. Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. PLoS One 2014;9:e90953.
4. Hernandez-Ontiveros DG, Tajiri N, Acosta S, Giunta B, Tan J, Borlongan CV, et al. Microglia activation as a biomarker for traumatic brain injury. Front Neurol 2013;4:30.
5. Yu S, Kaneko Y, Bae E, Stahl CE, Wang Y, van Loveren H, et al. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain Res 2009;1287:157-63.
6. Niyonkuruc W, Wagner AK, Ozawa H, Amin K, Goyal A, Fabio A, et al. Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: A practical example. J Neurotrauma 2013;30:938-45.
7. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974;2:81-4.
8. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008;25:719-38.
9. Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N. Long-term neurologic outcomes after traumatic brain injury. J Head Trauma Rehabil 2009;24:439-51.
10. Cerecedo-López CD, Kim-Lee JH, Hernandez D, Acosta SA, Borlongan CV. Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury. Med Hypotheses 2014;82:171-4.
11. Diamantis, T., Gonzales-Portillo C, Gonzales-Portillo GS, Staples M, Borlongan MC, Hernandez D, et al. Diabetes insipidus contributes to traumatic brain injury pathology via CD36 neuroinflammation. Med Hypotheses 2013;81:936-9.
12. Parikh S, Koch M, Narayan RK. Traumatic brain injury. Int Anesthesiol Clin 2007;45:119-35.
13. Malkesman O, Tucker LB, Ozl J, McCabe JT. Traumatic brain injury – Modeling neuropsychiatric symptoms in rodents. Front Neurol 2013;4:157.
14. Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, et al. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J Cell Physiol 2015;230:1024-32.
15. Stefanis L. A-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2012;2:a009399.
16. Su E, Bell MJ, Wisienski SR, Adelson PD, Janesko-Feldman KL, Salonia R, et al. A-synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: The effect of therapeutic hypothermia. Dev Neurosci 2010;32:385-95.
17. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 2007;208:185-92.
18. Tajiri N, Kellogg SL, Shimizu A, Arendash GW, Borlongan CV. Traumatic brain injury precipitates cognitive impairment and extracellular αβ aggregation in Alzheimer’s disease transgenic mice. PLoS One 2013;8:e78851.
19. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010;25:72-80.
20. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic brain injury-related emergency department visits, hospitalizations, and deaths – United States, 2007 and 2013. MMWR Surveill Summ 2017;66:1-6.
21. Machamer JE, Temkin NR, Dickmen SS. Neurobehavioral outcome in persons with violent or nonviolent traumatic brain injury. J Head Trauma Rehabil 2003;18:387-97.
22. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. On the contributions of apoptosis and necrosis. Brain Res Bull 2013;81:675-80.
23. Fujino M, Ohno M, Kato K, Nishii K, Eda K. Traumatic brain injury in adult rats. Brain Res 2009;1280:172-7.
24. Warden D. Military TBI during the Iraq and Afghanistan wars. J Head Trauma Rehabil 2003;18:387-97.
25. Riggio S. Traumatic brain injury. Int Anesthesiol Clin 2007;45:119-35.
26. Bryan CJ. Multiple traumatic brain injury and concussive syndrome. J Head Trauma Rehabil 1999;14:281-309.
27. Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, et al. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J Cell Physiol 2015;230:1024-32.
28. Tramontana MG, Cowan RL, Zald D, Prokop JW, Mott TF, McConnon ML, Rieger BP. Subacute to chronic mild traumatic brain injury: The effect of therapeutic hypothermia. Dev Neurosci 2010;32:385-95.
29. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 2007;208:185-92.
30. Tajiri N, Kellogg SL, Shimizu A, Arendash GW, Borlongan CV. Traumatic brain injury precipitates cognitive impairment and extracellular αβ aggregation in Alzheimer’s disease transgenic mice. PLoS One 2013;8:e78851.
31. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond DM, et al. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PLoS One 2013;8:e53376.
32. Glover LE, Tajiri N, Lau T, Kaneko Y, van Loveren H, Borlongan CV, et al. Immediate, but not delayed, microsurgical skull reconstruction exacerbates brain damage in experimental traumatic brain injury model. PLoS One 2012;7:e33646.
33. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: Bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013;698:6-18.
34. Quintard H, Patet C, Suys T, Marques-Vidal P, Oddo M. Normobaric hyperoxia is associated with increased cerebral excitotoxicity after severe traumatic brain injury. Neurocrit Care 2015;22:243-50.
35. Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C, et al. Neurodegeneration in excitoxicticity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998;46:281-309.
36. Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 2010;15:1382-402.
37. Dasuri K, Zhang L, Keller JN. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic Biol Med 2013;62:170-85.
38. Mutinati M, Pantaleo M, Roncetti M, Piccinni M, Rizzo A, Sciosci RL, et al. Oxidative stress in neonatology: A review. Reprod Domest Anim 2014;49:7-16.
39. Wang JF, Wang HD, Cong ZX, Zhou XM, Xu JG, Jia Y, et al. Puerarin ameliorates oxidative stress in a rodent model of traumatic brain injury. J Surg Res 2014;186:328-37.
40. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X, et al. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochem Biophys Acta 2014;1842:1240-7.
41. Hayashi T, Kaneko Y, Yu S, Bae E, Stahl CE, Kawase T, et al. Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats. Brain Res 2009;1280:172-7.
42. Qi L, Zhang T, Wang J, Zhang Z, Zhai Y, Yang GY, et al. Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke. Biochem Biophys Res Commun 2014;444:182-8.
43. Zhu KJ, Huang H, Chu H, Yu H, Zhang SM. Alterations in enterocyte mitochondrial respiratory function and enzyme activation in human tissues following experimental ischemic injury. J Bioenerg Biomembr 2008;40:339-50.
activities in gastrointestinal dysfunction following brain injury. World J Gastroenterol 2014;20:9585-91.

54. Mustafa AG, Singh IN, Wang J, Carrico KM, Hall ED. Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals. J Neurochem 2010;114:271-80.

55. Mbye LH, Singh IN, Sullivan PG, Springer JE, Hall ED. Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. Exp Neurol 2008;209:243-53.

56. Cheng G, Kong RH, Zhang LM, Zhang JN. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol 2012;167:699-719.

57. Shojo H, Kaneko Y, Mabuchi T, Kibayashi K, Adachi N, Borlongan CV, et al. Genetic and histologic evidence implicates role of inflammation in traumatic brain injury-induced apoptosis in the rat cerebral cortex following moderate concussion injury. Neuroscience 2010;171:1273-82.

58. Chhodobski A, Zink BJ, Szmydzynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res 2011;2:492-516.

59. Pop V, Sorensen DW, Kamper JE, Aja DO, Murphy MP, Head E, et al. Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood. J Cereb Blood Flow Metab 2013;33:205-14.

60. Yu F, Wang Z, Tanaka M, Chiu CT, Leeds P, Zhang Y, et al. Posttrauma cotreatment with lithium and valproate: Reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosci 2013;33:766-73.

61. Yang SH, Gustafson J, Gangidine M, Stepin D, Schuster R, Pritts TA, et al. A murine model of mild traumatic brain injury exhibiting cognitive and motor deficits. J Surg Res 2013;184:981-8.

62. Giunta B, Obregon D, Velisettty R, Sanberg PR, Borlongan CV, Tan J, et al. The immunology of traumatic brain injury: A prime target for Alzheimer’s disease prevention. J Neuroinflammation 2012;9:185.

63. Tajiri N, Hernandez D, Acosta S, Shinozuka K, Ishikawa H, Ehrhart J, et al. Suppressed cytokine expression immediately following traumatic brain injury in neonatal rats indicates an expeditious endogenous anti-inflammatory response. Brain Res 2014;1559:65-71.

64. Flüter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol 2014;192:2339-48.

65. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J Neurotrauma 2001;18:1295-311.

66. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain Behav Immun 2012;26:1191-201.

67. Ransohoff RM. The chemokine system in neuroinflammation: An update. J Infect Dis 2002;186 Suppl 2:S152-6.

68. Chhor V, Le Charpentier T, Lebon S, Oré MV, Celador IL, Ransohoff RM. The chemokine system in neuroinflammation: An update. J Infect Dis 2002;186 Suppl 2:S152-6.

69. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004;4:7.

70. Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, et al. Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-51.

71. Rodrigues MC, Glover LE, Weinbren N, Rizzi JA, Ishikawa H, Shinozuka K, et al. Toward personalized cell therapies: Autologous menstrual blood cells for stroke. J Biomed Biotechnol 2011;2011:194720.

72. Szmydzynger-Chodobska J, Gandy JR, Varone A, Shan R, Chodobski A. Synergistic interactions between cytokines and AVP at the blood-CSF barrier result in increased chemokine production and augmented influx of leukocytes after brain injury. PLoS One 2013;8:e79328.

73. Ye X, Fagan SC, Hall ED, Edwards D, Borlongan CV. Melatonin-based therapeutics for neuroprotection in stroke. Int J Mol Sci 2012;13:111.

74. Kovesdi E, Kannaksh A, Wingo D, Ahmed F, Grunberg NE, Long JB, et al. Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. Front Neurol 2012;3:111.

75. Homsi S, Fedderico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, et al. Minocycline effects on cerebral edema: Relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009;1291:132-22.

76. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010;7:22-30.

77. Guo ZD, Wu HT, Sun XC, Zhang XD, Zhang JH. Protection of minocycline on early brain injury after subarachnoid hemorrhage in rats. Acta Neurochir Suppl 2011;110:71-4.

78. Kelso ML, Scheff NN, Scheff SW, Pauly JR. Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury. Neurosci Lett 2011;488:60-4.

79. Camplto M, Ahmad A, Crupi R, Impellizzeri D, Morabito R, Esposito E, et al. Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J Endocrinol 2013;217:291-301.

80. Senol N, Naztroglu M. Melatonin reduces traumatic brain injury-induced oxidative stress in the cerebral cortex and blood of rats. Neuro Regen Res 2014;9:1112-6.

81. Gonzales-Portillo GS, Lozano D, Aguirre D, Reyes S, Borlongan CV, Tajiri N, et al. An update on the use of melatonin as a stroke therapeutic. Minerva Med 2015;106:169-75.

82. Shinozuka K, Staples M, Borlongan CV. Melatonin-based therapies for neuroprotection in stroke. Int J Mol Sci 2013;14:8924-47.

83. Borlongan CV, Sumaya I, Doss D, Kumazaki M, Sakurai T, Hida H, et al. Melatonin-secreting pineal gland: A novel tissue source for neural transplantation therapy in stroke. Cell Transplant 2003;12:225-34.

84. Borlongan CV, Yamamoto M, Takei N, Kumazaki M, Ungsuparkom C, Hida H, et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 2000;14:1307-17.

85. Poulos SG, Borlongan CV. Artificial lighting conditions and melatonin alter motor performance in adult rats. Neurosci Lett 2000;280:33-6.
98. Tajiri N, Duncan K, Antoine A, Pabon M, Acosta S, de la Peña I, et al. Adult stem cell transplantation: Is gender a factor in stemness? Int J Mol Sci 2014;15:15225-43.
99. Antonucci I, Di Pietro R, Alfonso M, Centurione MA, Centurione L, Sancilio S, et al. Human second trimester amniotic fluid cells are able to create embryoid body-like structures in vitro and to show typical expression profiles of embryonic and primordial germ cells. Cell Transplant 2014;23:1501-15.
100. Liu R, Zhang Z, Lu Z, Borlongan C, Pan J, Chen J, et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev 2013;22:1053-62.
101. Antonucci I, Pantalone A, Tete S, Salini V, Borlongan CV, Hess D, et al. Amniotic fluid stem cells: A promising therapeutic resource for cell-based regenerative therapy. Curr Pharm Des 2012;18:1846-63.
102. Rodrigues MC, Voltarelli J, Sanberg PR, Allickson JG, Kuzmin-Nichols N, Garbuzova-Davis S, et al. Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke. Neurosci Biobehav Rev 2012;36:177-90.
103. de la Peña I, Sanberg PR, Acosta S, Lin SZ, Borlongan CV. Umbilical cord blood cell and granulocyte-colony stimulating factor: Combination therapy for traumatic brain injury. Regen Med 2014;9:409-12.
104. Zhang R, Liu Y, Yan K, Chen L, Chen XR, Li P, et al. Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation 2013;10:106.
105. Borlongan CV, Glover LE, Tajiri N, Kaneyo K, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: Therapeutic implications for stroke and other neurological disorders. Prog Neurobiol 2011;95:213-28.
106. Borlongan CV. Bone marrow stem cell mobilization in stroke: A ‘bonehead’ may be good after all! Leukemia 2011;25:1674-86.
107. Watanabe J, Shetty AK, Hattiangady B, Kim DK, Foraker JE, Nishida H, et al. Administration of TSG-6 improves memory after traumatic brain injury in mice. Neurobiol Dis 2013;59:86-99.
108. Russo I, Barlati S, Bosetti F. Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem 2011;116:947-56.
109. Yoo SW, Chang DY, Lee HS, Kim GH, Park JS, Ryu BY, et al. Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-β. Neurobiol Dis 2013;58:249-57.
110. Dela Peña I, Sanberg PR, Acosta S, Tajiri N, Lin SZ, Borlongan CV, et al. Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: Aging as a comorbidity factor. J Neurosurg Sci 2014;58:145-9.